Navigation Links
Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine

VIENNA, March 31 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it will host a conference call today to discuss the U.S. Food and Drug Administration's (FDA) approval of IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE). The initial target for use of Intercell's vaccine - the only such product currently manufactured for the U.S. market - will be adult travelers and military personnel who visit or are deployed to affected countries, including India, China, and other parts of Asia.

    Conference Call Details

    Time: 3 p.m. CET, 2 p.m. GMT and 9 a.m. EDT.

    Chairpersons: Gerd Zettlmeissl (CEO) and Thomas Lingelbach (COO and
    Managing Director Intercell Biomedical Ltd., Scotland)

    Austria: +43 (0)2682 205 62 92
    Germany: +49 (0)69 589 990 507
    Switzerland: +41 (0)434 56 92 61
    US: +1 334 323 62 01
    UK: +44 (0)20 7131 2799

Please quote "Intercell Call" and an operator will then put you through to the Intercell conference call.

The presentation will be made available on the Intercell website prior to the conference call.

About Japanese Encephalitis

Japanese Encephalitis is a mosquito-borne infection that strikes 30,000 to 50,000 individuals a year, causing 10,000 to 15,000 deaths (both probably an underestimate due to underreporting and other factors). Up to 50 percent of survivors have persistent neurological sequelae. Japanese Encephalitis is the leading cause of viral neurological disease and disability in Asia and the most important viral encephalitis in Asia. The disease is most common in several developing countries in Asia, including India and China. As there is no specific treatment for JE, health care experts recommend vaccination as the only highly effective protection for the millions of travelers and military personnel who live in or travel to areas where the virus circulates.


Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization against the Japanese Encephalitis virus. The total development time of this vaccine took more than 10 years. The vaccine was developed under a Collaborative Research and Development Agreement with the Walter Reed Army Institute of Research, a biomedical research laboratory for the U.S. Department of Defense.

Intercell's Phase III trials for the vaccine found that the vaccine demonstrated excellent immunogenicity against Japanese Encephalitis and an overall clinical safety profile similar to placebo, combined with an excellent local tolerability profile. These data were published in The Lancet in December 2007:

  • The immunogenicity was comparable to that of the U.S. licensed product, JE-VAX(R).
  • Intercell's vaccine demonstrated an overall clinical safety profile similar to placebo.
  • Further, Intercell's Japanese Encephalitis vaccine had a more favorable local tolerability profile in the head-to-head study with JE-VAX(R).

About Intercell AG

Intercell AG is an innovative biotechnology company that designs and develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the company's first product on the market.

The Company's technology platforms include an antigen-discovery system, two proprietary adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin and the Statens Serum Institut.

The Company's development pipeline includes Phase II vaccine programs for Pseudomonas (in-house development) and S. aureus, which is being developed with Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter Phase III testing in 2009. Intercell is also in clinical trials of a vaccine enhancement patch with injected pandemic influenza vaccines (one shot plus patch). In addition, four other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit:

    Contact Intercell AG

    Intercell AG
    Lucia Malfent
    Head of Corporate Communications
    Campus Vienna Biocenter 3, A-1030 Vienna
    P: +43-1-20620-1303
    Mail to:

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
2. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
3. Iomai Stockholders Approve Merger With Intercell Subsidiary
4. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
5. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
6. New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced that ... closed system for isolating adipose-derived stem cells. The announcement starts a new phase toward ... SVF is a component of the lipoaspirate obtained from liposuction of excess adipose tissue. ...
(Date:11/30/2015)... 2015  An interventional radiology technique shows promise for helping ... of a study being presented today at the annual meeting ... (RSNA). --> --> ... interventional radiologists as a way to stop bleeding in emergency ... means of treating obesity is new. Mubin Syed ...
(Date:11/30/2015)... N.Y. , Nov. 30, 2015  Culprits ... by assistant chemistry professor Jan Halámek, is taking ...   --> ...   --> ... at UAlbany have discovered a straightforward concept for ...
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015 /PRNewswire/ ... property development company committed to the fostering and ... on the current and prospective initiatives designed to ... , Chief Executive Officer of Spherix. "Based on ... potential future licensees exceeds $50 billion and Spherix ...
Breaking Biology Technology:
(Date:10/29/2015)... Today, LifeBEAM , a leader ... a global leader in technical performance sports clothing ... advanced bio-sensing technology. The hat will allow fitness ... biometrics to improve overall training performance. As a ... bring together the most advanced technology, extensive understanding ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
Breaking Biology News(10 mins):